Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- (-) Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- (-) Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 211 Results
Insurance Switching and the Mismatch Between the Costs and Benefits of New Technologies
The peer-reviewed study examined the disconnect between the short-term budget impact of a treatment and its downstream effects on payers and society.
Why We Need A Serious Conversation About Health Spending
The government released its annual assessment on health spending in 2016 and the overall spending number came in at $3.3 trillion, up 4.3 percent from 2015. We know the easy fixes aren’t up to the…
NPC in Health Affairs Blog: It’s Time for a Serious Conversation About Health Care Spending
In a blog published today in Health Affairs, National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, noted that a serious conversation among all health care stakeholders is…
NAMI Weighs in on Value Assessment and ICER Engagement
Andrew Sperling, Director of Legislative Advocacy for the National Alliance on Mental Illness (NAMI), caught up with NPC President Dan Leonard to chat about concerns raised by mental health advocates…
Where Are They Now: Checking In With Former NPC Intern Dan Danielson
Dan Danielson, MS, currently a senior clinical manager at Premera Blue Cross, participated in NPC’s pharmaceutical internship program in 1993. Mr. Danielson chatted with us to answer a few questions…
NPC Chief Science Officer Robert Dubois to Address Value in Personalized Medicine at 13th Annual Personalized Medicine Conference
At the 13th Annual Personalized Medicine Conference, hosted by the Personalized Medicine Coalition, NPC's Dr. Robert W. Dubois will explore why health care stakeholder viewpoints on the value of a…
IVI Introduces Transparent Approach for Value Assessment
The Innovation and Value Initiative (IVI) released its first assessment of treatments for rheumatoid arthritis using its new approach toward value assessment. NPC is still evaluating IVI’s new…
Where Are They Now: Checking In With Former NPC Fellow Chuck Shih
Chuck Shih, PhD, MHS, currently Senior Officer, Drug Spending at Pew Charitable Trusts, was the 2013-2015 NPC Health Policy Fellow as part of a partnership with the George Washington University…
What’s Contributing to Unnecessary Health Spending?
Reducing low-value care—health care that is cost-inefficient and clinically ineffective—remains a front burner issue for health care stakeholders. It hasn’t been easy to root out or measure low-value…
NPC in AJPB: Guiding Practices for Patient-Centered Value Assessment
In response to growing concerns about health care costs, during the past few years, we’ve seen an increase in the development and use of value assessment frameworks. A variety of physician, payer and…
Appropriate Value Assessment Entails A Broad Perspective Of Impact and A Comprehensive Use of Evidence
NPC Chief Science Officer and Executive Vice President Robert W. Dubois looks at recent publications that highlight the need to consider a societal perspective when assessing value and utilize real…
An Important Dialogue About Orphan Drugs
While it’s encouraging to see that the Institute for Clinical and Economic Review (ICER) began the conversation about the value of orphan drugs, treatments that are used for conditions affecting very…
An Opportunity to Thoughtfully and Holistically Address Health Care Spending
The Medicare Trustees Annual Report issued last week was a mix of positive news and a stark reminder that we need to find thoughtful solutions to ensure that the Medicare program will remain solvent…
Asking the Right Questions About Our Health Care System Costs
With health news headlines focused on drug prices, the Senate Committee on Health, Education, Labor and Pensions is holding a hearing today titled, "The Cost of Prescription Drugs: How the Drug…
Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study
Researchers conducted cross-framework comparisons of multiple myeloma assessments using four value assessment frameworks and examined the consistency of findings across three case studies.
NPC is Going to ISPOR’s 22nd Annual International Meeting – Are You?
NPC will be at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, held May 20-24 in Boston, to lead issue panels and workshops,…
Value Assessment Frameworks: Are They Up To The Challenge?
In this article published on the Health Affairs Blog, NPC researchers Dr. Robert Dubois and Kimberly Westrich ask: Are value assessment frameworks ready to compare the health and economic impacts of…
The Evolution of Value Assessment
A Health Affairs Blog post by NPC Chief Science Officer Robert Dubois, MD, PhD, and Vice President for Health Services Research Kimberly Westrich, MA, identified several key considerations that could…